drugset / Trial / NCT04361630

Recombinant Human Fibroblast Growth Factor-2 (rhFGF-2) In Gingival Recession Defects

NCT04361630 ↗

Phase 0 Completed 30 enrolled SVS Institute of Dental Sciences
NaSingle-groupOpen-labelPrevention

Summary

This study was a single-arm trial to obtain preliminary data on the efficacy of collagen membranes impregnated with recombinant human fibroblast growth factor (rhFGF-2) in the treatment of Miller's class I and class II gingival recessions.

Timeline

Start
2019-05-01
Primary completion
2019-11-01
Completion
2019-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject FGF-2 Protein / enzyme biologic 10 ng/ml —

Indications